

## Psychosocial Predictors of Medication Adherence among Persons Living with HIV

Aurélie Gauchet, Cyril Tarquinio, and Gustave Fischer

5 *Background:* Since the introduction of highly active antiretroviral therapy (HAART), many have learned to live with HIV as a chronic illness. Adherence to medical regimens is extremely important for HIV patients. *Purpose:* To examine the extent to which medication adherence among HIV patients is related to social and psychological variables. *Method:* Data were gathered among 127 HIV patients (aged from 10 18–65 years) recruited at their quarterly consultation at Metz Hospital (France). Subjects completed a self-report adherence to medication scale, the Illness Perception Questionnaire (IPQ), the Beliefs about Medicine Questionnaire (BMQ), a French Value System Scale, a treatment satisfaction scale, and sociodemographic measures. *Results:* Analyses revealed significant associations between adherence and patients' 15 beliefs about treatment, satisfaction with treatment, confidence in the physician, some values ("other people," "god and children"), and duration of treatment and illness. *Conclusion:* The data suggest that patients' beliefs about treatment are formed to a certain degree in the patients' relationship with the physician. Furthermore, adherence seems to be related to personal values.

20 *Key words:* medication adherence, HIV infection, values, believes, self regulatory model

The efficacy of highly active antiretroviral therapy (HAART) offers the possibility of dramatic clinical improvement and prolonged life for persons infected with the human immunodeficiency virus-, or HIV (Karon, Fleming, Steketee, & De Cock, 2001; Murphy et al., 2001). Of the many factors that influence treatment success (e.g., disease stage, antiretroviral treatment history, and presence of resistant strains of HIV), adherence to antiretroviral medications seems crucial in determining the success or failure of antiretroviral therapy (Chesney et al., 2000b; Perno et al., 2002; Van Vaerenbergh et al., 2002). Even occasional nonadherence to HAART may result in virologic failure and the emergence of drug-resistant strains. In one study that documented the high levels of adherence needed for effective HAART, Paterson et al. (2000) reported that virologic failure occurred in 72% of individuals with less than 95% adherence but in only 22% of individuals with 95% or greater adherence.

Although it is widely recognized that adherence to HAART is vital to treatment success, adherence is often poor (Bangsberg et al., 2000; Lucas, Chaisson, & Moore, 1999; Liu et al., 2001; Nieuwkerk et al., 2001; Paterson et al., 2000). There are many potential reasons for poor adherence. The HAART regimen can be complex, often involving three or more medications, up to eight daily pills, and dietary restrictions. Many individuals experience immediate and long-term side effects including fatigue, nausea, diarrhea, insomnia, abnormal fat accumulation, taste alterations, and peripheral neuropathy (Ammassari et al., 2001; Chesney et al., 2000a). All these factors, combined with the long-term nature of the course of treatment, may result in poor adherence among seropositive individuals.

While there is growing consensus that multicomponent intervention approaches are more effective in enhancing adherence (Haynes, 2002; Roter et al., 1998; Wright, 2000), the mechanisms by which the interventions enhance adherence need clarification.

That situation led Reynolds (2003) to propose a model for antiretroviral (ARV) medication adherence, using Leventhal's self-regulation theory (Diefenbach & Leventhal, 1996; Leventhal et al., 1997) and supporting theoretical and empirical work (e.g., Alonzo & Reynolds, 1995; Reynolds & Alonzo, 2000). Leventhal's theory brings a patient-centered understanding to the dynamic factors involved in adherence.

Aurélie Gauchet, Department of Psychology, University of Miami, Coral Gables, FL; Cyril Tarquinio and Gustave Fischer, University of Metz, France.

The authors thank Charles S. Carver for comments on earlier versions of the manuscript and S. T. Calvin for statistical suggestions.

Correspondence concerning this article should be addressed to Aurélie Gauchet, Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL 33124-0751. E-mail: GauchetA@aol.com

65 This theory suggest that people seek to understand their  
illness by developing a working model or representa-  
tion of what the illness is, its causes, its effects, how  
long it will last, and whether it can be cured or con-  
70 trolled. Representations are elaborated through the per-  
son's idiosyncratic symptom and illness episodes and  
information obtained through social and cultural chan-  
nels. These representations do not necessarily conform  
to scientific views, but they have been found to guide  
health behaviors (Reynolds, 2003).

75 In this view, people are thought to be motivated to  
minimize their health-related risks and act to reduce  
health threats in ways consistent with their perceptions  
of them. This model suggests that adherence to ARV  
medications will be influenced by whether adherence  
80 makes sense to the patient, given his or her particu-  
lar illness representation. It can be readily seen that  
several factors that have been identified as particularly  
important to ARV adherence (e.g., illness experiences,  
interactions with others, cognitive function) may in-  
volve the individual's HIV illness representation.

85 Illness representations are not the only represen-  
tations that people form. They may also form represen-  
tations of treatments. It has been suggested that  
decisions about taking medication are likely to be in-  
formed by beliefs about the medicines as well as beliefs  
90 about the illness they are intended to treat or prevent  
(Horne, 1997). This principle is recognized in a recent  
report from the Royal Pharmaceutical Society of Great  
Britain, which has identified the role of medication  
beliefs in treatment adherence as a priority for future  
95 research (Marinker, 1997; Royal Pharmaceutical Soci-  
ety of Great Britain, 1997). Moreover, necessity beliefs  
and concerns have been shown to relate to adherence  
in a range of chronic illness (Horne et al., 2004).

100 The patient-provider relationship has been identi-  
fied as another important factor influencing adherence  
to treatment (Roberts, 2002). Aspects of the patient-  
provider relationship including trust, consistency, and  
continued interaction have been identified as being  
105 particularly important (Baken et al., 2000; Ickovics  
& Meisler, 1997; Singh et al., 1996). Further, patient  
adherence to medications has been enhanced when  
providers give clear explanations and provide full dis-  
closure of potential adverse events, and when they offer  
110 encouragement, reassurance, and support (Davis et al.,  
1997). This pathway is the main subject of the study  
reported here. In this study, we want to test whether  
confidence in physician predicts medication adherence  
directly, and may also predict it indirectly, through pa-  
tients' beliefs about treatment.

115 Another class of variable that appears relevant to  
the problem of adherence is values. Many authors  
have demonstrated the link between values and be-  
haviors (Rokeach, 1973; Schwartz, 1992; Fischer &  
Tarquinio, 2002). Indeed, values are often considered  
120 as representing the underpinnings of behavior. In this

view, people create a system of personal values from  
their experiences with their physical and social envi-  
ronment, their culture, and so on, and they then pro-  
ceed to act from this system of values. To put it dif-  
125 ferently, people decide what is important for them and  
act accordingly. For instance, we wanted to show how  
values like "spirituality" influence medication adher-  
ence. Although the effect of spirituality on medica-  
tion adherence per se is undocumented, persons di-  
agnosed with life-threatening illness such as cancer 130  
and HIV/AIDS have reported high levels of spiritual-  
ity (Connor, Wicker, & Germino, 1990; Jenkins, 1995;  
Zinnbauer et al., 1997), which have been highly corre-  
lated with psychological adaptation and good health  
outcomes (Kaczorowski, 1989; Simoni, Kerwin, & 135  
Martone, 2002).

Other recent authors focused on models of adher-  
ence with HAART. The most important factors seem  
to be social support and positive provider interactions  
(Simoni et al., 2006; Johnson et al., 2006b; Ironson 140  
et al., 2005) and also adherence information (regi-  
men, side effects, beliefs about treatment; Starace et  
al., 2006; Johnson et al., 2006a).

In the present study, we examined how values, con-  
fidence in one's physician, and patients' beliefs about 145  
their treatment relate to medication adherence. We  
chose these factors from the self-regulatory model of  
antiretroviral adherence (Reynolds, 2003). We used  
structural equation modelling in a diverse sample of 150  
HIV-positive men and women to test whether confi-  
dence in one's physician was an important factor for  
patients' beliefs about treatment and for their medi-  
cation adherence. Moreover, we wanted to analyse  
the contribution of some values (importance of others,  
155 spirituality) to medication adherence.

## Method

Data for these analyses came from a cross-sectional  
study that investigated the relations of psychosocial  
variables to medication adherence among HIV-positive  
160 men and women. Data were collected during 2001.

## Participants

HIV-positive adult men and women between the  
ages of 18 and 65 years who were currently prescribed  
HAART were eligible for inclusion in this study. No  
165 patient refused to participate in this study. Participants  
were recruited from the Regional Hospital Centre in  
Metz (France) during their quarterly consultation. Ini-  
tially, 175 patients responded to recruitment efforts  
and were screened for the study. After a preliminary  
170 introduction to the study, 48 did not meet eligibility  
criteria. Patients were included if they had been pre-  
scribed some medicines for regular use in the treatment  
of their illness for at least two months prior to the study,

PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

175 if they are at least 18 years, if they are not psychotic  
or demented, and if they could read and understand  
the questionnaire and felt well enough to complete it.  
The most common reasons for exclusion included partic-  
180 ipation in other clinical research trials, no current  
prescription for antiretroviral medication, inability to  
read or write French, or evidence of significant cog-  
nitive impairment. Data from 99 men and 28 women  
were used in the analyses. The characteristics of the  
main sample are shown in Table 1 and are described in  
more detail below.

185 The majority of the sample was White (84.3%),  
with 12.6% being Black/African. Thus, the sample  
is representative of people living with HIV/AIDS in  
France, with African women slightly underrepresented  
and White men and women slightly overrepresented  
190 (Organisation Mondiale de la Santé, 2002). A slight  
majority (59.1%) had a high school diploma or less  
education. The sample was fairly evenly divided be-  
tween individuals who described their sexual orien-  
tation as exclusively heterosexual (56%) and all the  
195 others (44%). The average age of the sample was 40  
years (SD = 9.20) and the mean time since HIV di-  
agnosis was 96 months (SD = 53). Participants were  
prescribed an average of 8 (SD = 3.9) daily antiretro-  
viral pills.

200 **Procedure**

Informed consent was obtained from all participants  
prior to participation. Qualified participants completed  
a battery of psychosocial instruments via face-to-face  
structured interviews and self-report formats. Each pa-  
205 tient was met individually in a hospital office. The in-  
vestigator stressed that the study was being conducted  
by the University and was completely independent of  
the hospital, and that responses were anonymous and  
would not be seen by any of the staff involved in their  
210 care. It was hoped that this would decrease social desir-  
ability bias in responses (Abraham & Hampson, 1996).

**Measures**

*Medication Adherence.* A self-report adherence to  
medication scale was devised for this study. This  
215 scale was inspired by the medication adherence scale  
of Tarquinio, Fischer, and Grégoire (2000). Non-  
adherence was indicated by the tendency to forget to  
take medication and to deliberately adjust or alter the  
dose from that recommended by the physician. This  
220 scale comprises 16 adherence statements. Three items  
(e.g., “I sometimes forget to take my medicines” and  
“I sometimes alter the dose of my medication”) are  
scored on a 6-point Likert scale with reverse scoring  
(where 1 = always and 6 = never). The remaining thir-  
225 teen items (e.g., “I take the medicines prescribed by the  
physician” and “I respect the whole recommendations  
of my physician”) are phrased as direct statements per-

**Table 1.** Sociodemographic and Medical Features of the Sample

Variable	N = 127	% of Sample
Age (years)	M = 39.7	SD = 9.2
Gender		
Male	99	78
Female	28	22
Ethnicity		
White	107	84.3
Black/African	16	12.6
Other	4	3.1
Relationship		
status Single	60	47.2
Married	20	15.7
Divorced	14	11
Homosexual partnered	19	15
Heterosexual partnered	9	7.1
Widowed	5	3.9
Education		
< High school	27	21.3
High school	48	37.8
Some College	24	18.9
College graduate	28	22
HIV diagnosis		
1981–1990	29	23
1991–1996	48	38.1
1997–2002	49	38.9
HIV mode of transmission		
Homosexual intercourse	55	44
Heterosexual intercourse	30	24
Shared needles	15	12
Blood transfusion	4	3.2
Work accident	2	1.6
Unknown	19	15.2
Initiation of first HAART regimen		
<1996	24	20.7
1997–1999	51	44
2000–2002	41	35.3
Drug class		
Monotherapy	1	0.8
Bithery	8	6.7
Tritherapy	102	85.7
Quadritherapy	8	6.7
CD4 cell counts (cellules/mm <sup>3</sup> )		
>500	33	43.4
200–500	27	35.5
<200	16	21.1
Viral load		
Detectable	65	51.6
Undetectable	61	48.4
Medication side effects		
Yes	93	73.2
No	34	26.8

taining to the frequency of adjusting medication doses  
(scored on a 6-point scale where 1 = never and 6 = al-  
ways). A total medication adherence score is obtained  
230 by summing responses to each of the sixteen items.  
Scores ranged from 16 to 96, with higher scores indi-  
cating greater reported adherence.

*Values.* A scale of reported values was also devised  
for this study. This scale derives from the work of  
235 Rokeach (1973) and Schwartz (1992). HIV patients

were asked to indicate the importance of each value to them, before and after their disease. Items are scored with a 9-point Likert scale (where 0 = not at all important and 9 = very important). Principal component analysis on these items (using the non-orthogonal method of rotation, as recommended by Kline, 1994, and Cattell, 1995) yielded four categories of values, explaining 47% of the variance: “other people” (11 items: respect, tolerance, being understanding with others), “success” (11 items: have a good job, be competitive, richness), “God and children” (5 items: found a family, see the children grow up, believe in god), and “sexuality” (5 items: continue to have sex, the pleasure, love). We have chosen to use these categories of values (used in other studies about AIDS and cancer, Fischer & Tarquinio, 2002) to see their relations to medication adherence.

*Beliefs about Medicines Questionnaire (BMQ).* The BMQ (Horne et al., 1999) assesses commonly held beliefs about medicines. The BMQ is an 18-item scale used to assess beliefs about the medications one has been prescribed (10 items) and the use of medication in general (8 items). There are four subscales: Specific-Necessity (e.g., “Without my HAART I would be very ill”), Specific-Concerns (e.g., “I sometimes worry about the long-term effects of my HAART”), General-Overuse (e.g., “Doctors use too many medicines”), and General-Harm (e.g., “All medicines are poisons”). Responses to each statement were scored on a 5-point Likert scale (where 1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, and 5 = strongly agree).

*Confidence in Physician.* Participants were asked to indicate the level of their confidence in their physician (“how much are you confident in your physician”). The item was scored on a 5-point Likert scale (where 1 = strongly not confident and 5 = strongly confident). Most patients reported being very confident in their physician.

### Statistical Analyses

First we calculated descriptive statistics, including means, standard deviations, ranges, and alpha reliabilities of all psychosocial and medication adherence. Next, to identify potentially confounding variables that would need to be controlled in later analyses, we used bivariate analyses (i.e., Pearson correlations, *t*-tests, and chi-squares) to examine the association of each measure of adherence with sociodemographic factor (i.e., sex, ethnicity, age, education, sexual orientation, and relationship status) and medical-related variables (i.e., time since HIV diagnosis, time since initiation of first HAART regimen, drug class, number of medication in regimen, and viral load), as well as side effects.

Finally, structural equation modelling (SEM) was used to evaluate the proposed model. SEM examines the structural relationships between values, confidence in the physician, and patients’ beliefs about treatment, and medication adherence.

SEM analysis was evaluated with the maximum-likelihood estimation and performed with STATISTICA software (version 6.1, Sepath model). Consistent with current recommendations, several goodness-of-fit indices were used in addition to the chi-square statistic that is sensitive to both the assumption of normality and sample size. Specifically, the overall model fit was assessed by examining the root-mean-square error of approximation (RMSEA) index, with values around .05 (the lower bound of the 90% CI under .05) indicating adequate fit (Bollen & Long, 1993; Browne & Cudeck, 1993); the standardized root-mean-square residual (SRMR) index, with values less than .09 as a criterion (Hu & Bentler, 1999); and the comparative fit index (CFI; Bentler, 1990), which indicates an adequate fit with values around .90 or greater (Newcomb, 1990, 1994).

## Results

### Descriptive Data

Means, standard deviations, ranges, and alpha reliabilities of all psychosocial measures are presented in Table 2. The table also includes means, standard deviations and alpha reliabilities for the level of adherence as assessed by the medication adherence scale.

### Bivariate Analyses

In bivariate analyses, none of the adherence variables were related to any sociodemographic or medical-related variable or to side effects (see Table 3). Therefore, none of these variables were controlled in SEM. The only variables significantly related to

**Table 2.** Descriptive Statistics for Study Variables among 127 HIV-Positive Individuals

Factor and Indicators	Range	M	SD	Alpha Reliability
Values	0–9	7.68	1.08	.80
Other people	0–9	5.50	1.69	.78
Success	0–9	4.83	2.34	.69
God and children	0–9	7.53	1.53	.75
Sexuality	0–25	21.79	5.31	.72
BMQ				
Specific-Necessity	0–25	16.06	4.47	.68
Specific-Concerns	0–20	10.92	3.28	.64
General-Overuse	0–20	9.77	3.06	.70
General-Harm	0–5	4.59	0.63	—
Confidence with physician Adherence	0–96	81.37	9.61	.83

Note. BMQ = Beliefs about Medicine Questionnaire.

PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

**Table 3.** *Determinants of Medication Adherence*

Variables	Modalities	Medication Adherence Score				
		N <sup>1</sup>	m	σ	t	p
Age	<39 yrs	60	5.02	0.7	-1.18	NS
	>39 yrs	62	5.15	0.4		
Educational experience	<College	72	5.06	0.6	-0.50	NS
	>College	50	5.11	0.5		
Gender	Male	95	5.03	0.60	-2.02	NS
	Female	27	5.29	0.5		
Relationship status	Single	57	5.10	0.5	-0.53	NS
	Partnered or married	20	5.17	0.4		
HIV mode of transmission	Sexual intercourse	82	5.45	0.7	-0.25	NS
	Blood transfusion	38	5.50	0.6		
Sexual orientation	Homosexual	53	5.40	0.6	-1.68	NS
	Heterosexual	29	5.53	0.7		
Drug class	Mono./Bitherapy	9	4.73	0.5	-2.04	NS
	Tri./Quadritherapy	110	5.13	0.6		
Side effect	Yes	89	5.04	0.6	-1.37	NS
	No	33	5.21	0.5		
Viral load	Detectable	63	5.37	0.7	-1.73	NS
	Undetectable	58	5.55	0.6		
Confidence in physician	Confident	41	5.24	0.7	-2.9	.004
	Very confident	81	5.58	0.6		
Confidence in therapy	Not at all/Not confident	29	5.08	0.8	-3.9	.000
	Confident/Very confident	93	5.58	0.5		
Confidence in medicine	Not at all/Not confident	34	5.14	0.8	-2.4	.018
	Confident/Very confident	88	5.59	0.5		
Beliefs in benefit of therapy	Yes	63	5.63	0.5	3.9	.000
	No	59	5.28	0.7		
Improvement of QoL with treatment	Yes	78	5.57	0.5	3.4	.001
	No	44	5.26	0.7		

<sup>1</sup>The variations observed in the size of the sample are due to missing data (subjects did not want to or could not answer to some questions).

adherence were confidence in physician and confidence with therapy.

We also developed a multivariate model on medication adherence (see Table 4). The variables significantly contributing to medication adherence were du-

ration of treatment, duration of HIV infection (in years) and confidence in physician.

**Model Testing with SEM**

We wanted to test the associations of values, confidence in physician, patients’ beliefs about treatment, and medication adherence. We restricted our model to include only variables that correlated with medication adherence (see Table 5). We included three classes of values (“other people,” “success,” and “God and children”); confidence in one’s physician; two of patients’ beliefs about treatment (specific-concern and general-harm); and the score for total medication adherence as the end-point of the predictive path.

We tested whether confidence in physician would relate directly to medication adherence, and would relate indirectly, through patients’ beliefs about treatment. We also tested the influence of values on medication adherence. Accordingly, we tested a model with three “categories” of predictors of medication adherence: values, confidence in physician, and patients’ beliefs about treatment. This model also specified

**Table 4.** *A Multivariate Model on Medication Adherence among 127 HIV-Positive Individuals*

Variables	Medication Adherence		
	B	t	p
Constant	74.39	1.09	.28
Initiation of first HAART regimen (in years)	-0.06	-0.59	.55
Duration of treatment	-0.25	-2.10	.04
Time since HIV diagnosis (in years)	0.29	2.47	.01
Number of prescribed medicines	-0.09	-0.80	.42
CD4 cells count	-0.10	-0.94	.34
Confidence in physician	0.30	2.40	.02
Quality of life	0.21	1.69	.09

Note: Model Characteristics R multiple = .60; R<sup>2</sup> adjusted = .36; F(7,58) = 4,74, p = .000.

**Table 5.** Intercorrelations among Variables in the Study

	BMQ Specific Necessity	BMQ Specific Concern	BMQ General Harm	BMQ General Overuse	Physician's Confidence	Values Other People	Values Sexuality	Values God and Children	Values Success
BMQ specific concern	-,06								
BMQ general harm	-,22*	,39**							
BMQ general overuse	-,18*	,25**	,54**						
Physician's confidence	,27**	-,15	-,26**	-,33**					
Values Other people	,17*	-,04	-,04	-,10	,17*				
Values Sexuality	-,00	,13	,13	,11	,02	,27**			
Values God and children	,11	,19*	,10	,04	,09	,45**	,18*		
Values Success	-,10	-,07	-,02	-,03	,24**	,31**	,41**	,06	
Adherence	,31**	-,04	-,25**	-,21*	,31**	,27**	,01	,17*	,20*


\* $p < 0.05$ ; \*\* $p < 0.01$ .

physician's confidence as influencing patients' beliefs about treatment.

The overall model has an adequate fit to the data,  $X^2(120, N = 127) = 23.16, p = .001, CFI = .96, RMSEA = 0.05$  (95% confidence interval = 0.03–0.06), SRMR = 0.07, and all factor loading and specified paths were significant (see Figure 1). In this model, the effect of physician's confidence on adherence is specified to be mediated in part by patients' beliefs about treatment. Greater confidence in the physician had a direct path to adherence. Confidence also had a positive path to stronger beliefs about the necessity of the antiretroviral treatment, which related to greater ad-

herence, and a negative path to the belief that medicines are generally harmful, which related to lower adherence. There were also direct paths from two classes of values ("others" and "God and children") to greater medication adherence.

This, of course, is not the only model that one might specify. It might be argued, for example, that beliefs about medicine influence confidence in the physician, rather than vice versa. To determine how well such an alternative model would account for the relationships among the variables, we also tested a model in which the order of paths for confidence in physician and beliefs about treatment was reversed. This model has a



**Figure 1.** Structural equation model of psychosocial influences on medication adherence among persons living with HIV. All paths are significant ( $p < .05$ ). Model fit statistics were as follows :  $X^2(120, N = 127) = 23.16, p = .001$ , comparative fit index = .96, root-mean-square error of approximation = 0.05 (95% confidence interval = 0.03–0.06), standardized root-mean-square residual = 0.07.

fit that was less optimal:  $X^2(124, N = 127) = 14.84$ ,  
 $p = .001$ , CFI = .95, RMSEA = 0.09 (95% confi-  
380 dence interval = 0.07–0.1), SRMR = 0.08. The first  
model (shown in Figure 1) therefore was retained as the  
model that best accounted for the pattern of observed  
relationships among variables.

### Discussion

385 The present study examines relationships among  
values, confidence in physician, patients' beliefs about  
treatment, and medication adherence in a diverse sam-  
ple of men and women living with HIV. As hypoth-  
esized, greater confidence in one's physician was re-  
390 lated to greater adherence. Moreover, we found that  
values and patients' beliefs about treatment also re-  
lated to adherence. The effect of confidence in the  
physician was in part mediated by patients' beliefs  
about treatment. These results are consistent with the  
395 self-regulatory model for ARV adherence (Reynolds,  
2003). This model suggests that the association be-  
tween the patient-provider relationship and medication  
adherence is mediated by HIV illness/medication rep-  
resentation. In other words, the relationship between  
400 confidence in physician and adherence is in part posi-  
tively mediated by patients' beliefs about the necessity  
of antiretroviral treatment and negatively mediated by  
patients' beliefs about the harmfulness of medication  
in general. The data are consistent with the position  
405 that patients' beliefs about treatment are formed in  
part from the patients' relation with the physician (the  
information that he or she gives about antiretroviral  
treatment, the side effects, the importance of taking  
medication regularly). This suggests that the patient-  
410 provider relationship is particularly important.

The present study improves on previous research  
by including all of the theorized variables in a compre-  
hensive model and testing this against an alternative  
415 model. Does the relationship between confidence in  
physician and beliefs about treatment also work in the  
opposite direction? Although our data did not support  
this direction of effects clearly, it is possible for the  
relationship to be bidirectional. Individuals may have  
some personal beliefs about their treatment and, for that  
420 reason, become more or less confident in the physician.  
Longitudinal modelling of confidence in physician and  
patients' beliefs about treatment will be necessary to  
fully understand how this process unfolds over time.

Our results also lend support to the direct link  
425 between certain personal values and medication ad-  
herence. Valuing tolerance, respectfulness, and under-  
standing toward others predicted greater adherence.  
Valuing family and beliefs in god also predicted greater  
adherence. These values ("other people" and "god  
430 and children") may be associated with social support,  
which is well known to be related to adherence (Pa-

terson et al., 2000; Simoni et al., 2006; Weaver et al.,  
2005). On the other hand, valuing "success" and "sex-  
uality" did not relate to adherence. These findings sug-  
435 gest that it may be useful to emphasize the relevance  
of certain values as a way of improving medication  
adherence.

In addition to theory building, our findings have  
implications for intervention development and clinical  
440 practice. They suggest that the social support (mea-  
sured by valuing other people) received from an af-  
firming other, an information-enhancing relationship,  
an empathic listener (measured by the confidence with  
physician), or a spiritual relationship is associated with  
445 improved medication adherence. Consequently, adher-  
ence may be increased through future efforts to im-  
prove individuals' access to social support, whether by  
encouraging them when safe and appropriate to con-  
fide in a partner or close friends or by facilitating their  
450 relationships with their medical care providers or with  
peers who are on similar medication regimens (Cohen  
et al., 2000; Uchino, 2004).

For spiritually inclined individuals, intervention fo-  
cused on spiritual coping that could help to main-  
455 tain a positive attitude and motivation toward health  
should be explored further. Such interventions could  
fill a culturally significant need for support (Jenkins &  
Pargament, 1995). Although we could not examine the  
effect of knowledge in our model (but we measured  
460 beliefs about treatment), prior research has suggested  
that it is at least a necessary, if not sufficient, factor in  
adherence and should be addressed. Information about  
specific medications, adherence strategies, the impor-  
465 tance of adherence, and the management of side effects  
needs to be communicated throughout the course of  
treatment and not just at initiation. Medication adher-  
ence training may also enhance the effects of HAART  
(Antoni et al., 2006).

Interventions for HIV-positive persons on HAART  
are especially needed (Simoni et al., 2003). Given  
470 the lingering stigma surrounding HIV/AIDS, social  
support may be especially important for persons on  
HAART.

The current study has several limitations that should  
475 be noted. First, the stability of results from structural  
equation models depends in part on having a large sam-  
ple size. This study would have benefited from a larger  
sample. Moreover, as previously noted, longitudinal  
modelling of the relationships between confidence in  
480 the physician and patients' beliefs about treatment is  
highly desirable to confirm the proposed relationships.  
In addition, because we recruited patients during their  
quarterly consultation and required our participants to  
be healthy enough to attend a number of assessment  
485 appointments, our results may not generalize to those  
individuals with serious co morbid medical conditions  
such as cancer or hepatitis, or advanced AIDS. Another  
limitation is the use of a single unvalidated item to

490 assess confidence in physician. Future research should  
use validated scales to assess multidimensional con-  
structs related to patient/physician relationships. Fi-  
nally, it is desirable that future studies use multiple  
methods of measuring adherence.

495 **The application of statistical modelling techniques  
has great potential to advance our understanding of how  
psychosocial and behavioural factors jointly influence  
health. The results of the present study reveal that confi-  
dence in the physician, mediated partly through pa-  
tients' beliefs about treatment, predict adherence to the  
500 medical regimen in men and women living with HIV.**

Future HIV medication adherence research should con-  
tinue to focus on appropriate measurement of con-  
structs (i.e., confidence with physician), the expansion  
of models to include additional constructs (i.e., social  
505 support may mediate the relation between values and  
adherence), and the application of findings to the devel-  
opment of interventions to enhance HAART adherence  
among men and women living with HIV.

510 Future research is needed also to validate this pre-  
liminary model, perhaps on larger and demographi-  
cally different samples and with respect to different  
chronic illness regimens. Only with a sound theoret-  
ical model can the pervasive problem of medication  
adherence among individuals with chronic illness be  
515 understood and effective interventions then devised to  
assist them.

## Q6

## References

- Abraham, C., & Hampson, S. E. (1996). A social cognition approach  
to health psychology: Philosophical and methodological issues.  
520 *Psychology and Health, 11*, 223–241.
- Alonzo, A. A., & Reynolds, N. R. (1995). Stigma, HIV, and  
AIDS: An exploration and elaboration of the illness trajec-  
tory surrounding HIV infection and AIDS. *Social Science and  
Medicine, 41*, 303–315.
- 525 Ammassari, A., Murri, R., Pezzotti, P., Paola Trotta, M., Ravasio,  
L., & De Longis, P., et al. (2001). Self-reported symptoms and  
medication side effects influence adherence to highly active  
antiretroviral therapy in persons with HIV-infection. *Journal of  
Acquired Immune Deficiency Syndromes, 28*, 445–449.
- 530 Anderson, J. C., & Gerbing, D. W. (1988). Structural equation mod-  
elling in practice: A review and recommended two-step ap-  
proach. *Psychological Bulletin, 103*, 411–423.
- Antoni, M. H., Carrico, A. W., Duran, R. E., Spitzer, S. S., Penedo,  
F., Ironson, G., Fletcher, M. A., Klimas, N., & Schneidermann,  
N. (2006). Randomized clinical trial of cognitive behavioral  
535 stress management on human immunodeficiency virus load in  
gay men treated with highly active antiretroviral therapy. *Psy-  
chosomatic Medicine, 68*, 143–151.
- Bakken, S., Holzemer, W. L., Brown, M. A., Powell-Cope, G.  
M., Turner, J. G., Jnouye, J., Nokes, K. M., & Corless, I. B.  
540 (2000). Relationships between perception of engagement with  
health care provider and demographic characteristics, health  
status, and adherence to therapeutic regimen in persons with  
HIV/AIDS. *AIDS Patient Care and STDs, 14*, 189–197.
- 545 Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R.,  
Holodniy, M., Sheiner, J. D., Chesney, M. A., & Moss, A.  
(2000). Adherence to protease inhibitors, HIV-1 viral load, and

- development of drug resistance in an indigent population. *AIDS, 14*, 357–366.
- Bentler, P. M. (1990). Comparative fit indexes in structural models. 550  
*Psychological Bulletin, 107*, 238–247.
- Bollen, K. A., & Long, J. S. (1993). Testing structural equation  
models. *Psychological Bulletin, 107*, 238–246.
- Browne, M. W., & Cudeck, R. (1993). Alternative ways of assessing  
model fit. In K. A. Bollen & J. S. Long (Eds.), *Testing structural* 555  
*equation models* (pp. 136–162). Newbury Park, CA: Sage.
- Cattell, R. B. (1995). The fallacy of five factors in the personality  
sphere. *The Psychologist, May*, 207–208.
- Chesney, M. A. (1997). Compliance: How you can help. *HIV New-* 560  
*lines, 7*, 67–72.
- Chesney, M. A. (2000). Factors affecting adherence to anti-  
retroviral therapy. *Clinical Infectious Diseases, 30*, S171–  
S176.
- Chesney, M. A., Ickowics, J. R., Chambers, D. B., Gifford, A. L.,  
Neidig, J., Zwickl, B., et al. (2000a). Self-reported adherence 565  
to antiretroviral medications among participants in HIV clinical  
trials: The AACTG adherence instruments. *AIDS Care, 12*,  
255–266.
- Chesney, M. A., Ickowics, J., Hecht, F. M., Sikipa, G., & Rabkin, J.  
(1999). Adherence: A necessity for successful HIV combina- 570  
tion therapy. *AIDS, 13*, 271–278.
- Chesney, M. A., Morin, M., & Sherr, L. (2000b). Adherence to HIV  
combination therapy. *Social Science & Medicine, 50*, 1599–  
1605.
- Cohen, S., Underwood, L. G., & Gottlieb, B. H. (2000). 575  
*Social support measurement and intervention: A guide for health and  
social scientists*. New York: Oxford University Press.
- Connor, A. P., Wicker, C. A., & Germino, B. B. (1990). Understand-  
ing the cancer patient's search for meaning. *Cancer Nursing, 13*,  
167–175. 580
- Davis, M. S. (1971). Variations in patient compliance with doc-  
tor advice: Medical practice and doctor-patient interaction.  
*Psychiatric Medicine, 2*, 31.
- Davis, M. S., Canniff, J. M., & Andradas, V. (1997). Success- 585  
ful ritonavir induction with intensive patient management.  
Fourth Conference on Retrovirus and Opportunistic Infections,  
Washington, DC.
- Diefenbach, M. A., & Leventhal, H. (1996). The common-sense  
model of illness representation: theoretical and practical con-  
siderations. *Journal of Social Distress and the Homeless, 5*, 590  
11–38.
- DiMatteo, M. R., Hays, R. D., & Prince, L. M. (1986). Relationship  
of physicians' non-verbal communication skills to patient satis-  
faction, appointment non-compliance, and physician workload. 595  
*Health Psychology, 5*, 581–594.
- DiMatteo, M. R., Sherbourne, C. D., Hays, R. D., Ordway, L.,  
Kravitz, R. L., McGlynn, E. A., Kaplan, S., & Rogers, W. H.  
(1993). Physicians' characteristics influence patients' adher-  
ence to medical treatment: Results from the Medical Outcomes  
Study. *Health Psychology, 12*, 93–102. 600
- Fischer, G. N., & Tarquinio, C. (2002). *Traité de psychologie de la  
santé*. Paris: Dunod.
- Horne, R. (1997). Representations of medication and treatment: Ad-  
vances in theory and measurement. In K. J. Petrie & J. Weinman  
(Eds.), *Perceptions of Health and Illness: Current Research and* 605  
*Applications* (pp. 155–187). London: Harwood Academic.
- Horne, R. (2003). Treatment perceptions and self-regulation. In L. D.  
Cameron & H. Leventhal (Eds.), *The self-regulation of health  
and illness behaviour* (pp. 138–153). London: Routledge Taylor  
& Francis. 610
- Horne, R., Buick, D., Fischer, M. Leake, H., Cooper, V., & Weinman,  
J. (2004). Doubts about necessity and concerns about adverse  
effects: Identifying the types of beliefs that are associated with  
non-adherence to HAART. *International Journal of STD &* 615  
*AIDS, 15*, 38–39.



## PSYCHOSOCIAL PREDICTORS OF MEDICATION ADHERENCE AMONG PERSONS LIVING WITH HIV

- Horne, R., & Weinman, J. (1999). Patient's beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *Journal of Psychosomatic Research*, *47*, 555–567.
- 620 Horne, R., & Weinman, J. (2002). Self-regulation and self-management in asthma: Exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. *Psychology and Health*, *17*, 17–32.
- 625 Horne, R., Weinman, J., & Hankins, M. (1999). The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology and Health*, *14*, 1–24.
- Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indices in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modelling*, *6*, 1–55.
- 630 Ickovics, J. R., & Meisler, A. W. (1997). Adherence in AIDS clinical trials: A framework for clinical research and clinical care. *Journal of Clinical Epidemiology*, *50*, 385–391.
- 635 Ironson, G., O'Cleirigh, C., Fletcher, M. A., Laurenceau, J. P., Balbin, E., Klimas, N., Schneidermann, N., & Solomon, G. (2005). Psychosocial factors predicts CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. *Psychosomatic Medicine*, *67*, 1013–1021.
- 640 Jenkins, R. A. (1995). Religion and HIV: Implications for research and intervention. *Journal of Social Issues*, *51*, 131–144.
- Jenkins, R. A., & Pargament, K. I. (1995). Religion and spirituality as resources for coping with cancer. In M. R. Somerfield (Ed.), *Psychosocial resource variables in cancer studies: Conceptual and measurement issues* (pp. 51–74). Binghamton, NY: Haworth Press.
- 645 Johnson, M. O., Elliott, T. R., Neilands, T. B., Morin, S. F., & Chesney, M. A. (2006a). A social problem-solving model of adherence to HIV medications. *Health Psychology*, *25*, 355–363.
- 650 Johnson, M. O., Chesney, M. A., Goldstein, R. B., Remien, R. H., Catz, S., Gore-Felton, C., Charlebois, E., & Morin, S. (2006b). Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A medication model. *AIDS Patient Care*, *20*, 258–268.
- 655 Kaczorowski, J. M. (1989). Spiritual well-being and anxiety in adults diagnosed with cancer. *Hospice Journal*, *5*, 105–115.
- Karon, J. M., Fleming, P. L., Steketee, R. W., & De Cock, K. M. (2001). HIV in the United States at the turn of the century. *American Journal of Public Health*, *91*, 1060–1068.
- 660 Kline, P. (1994). *An Easy Guide to Factor Analysis*. London/New York: Routledge.
- Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense representation of illness danger. In S. Rachman (Ed.), *Contributions to Medical Psychology*. Oxford: Pergamon Press.
- 665 Leventhal, H., Zimmerman, R., & Gutmann, M. (1984). *Compliance: A self-regulation perspective*. In W. D. Gentry (Ed.), *Handbook of Behavioral Medicine*. New York: Guilford.
- Q8 Lenventhal, H., & Cameron, L. (1987). Behavioural theories and the problem of compliance. *Patient Education and Counselling*, *10*, 117–138.
- 670 Leventhal, H., Diefenbach, M., & Leventhal, E. A. (1992). Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. *Cognitive Therapy and Research*, *16*, 143–163.
- 675 Leventhal, H., Benyamini, Y., Brownlee, S., Diefenbach, M., Leventhal, E. A., Patrick-Miller, L., & Robitaille, C. (1997). Illness representations: Theoretical foundations. In K. J. Petrie & J. A. Weinman (Eds.), *Perceptions of health and illness: Current research and applications* (pp. 19–45). Singapore: Harwood Academic.
- 680 Liu, H., Golin, C. E., Miller, L., Hays, R., Beck, K., Sanandaji, S., Christian, J., Maldonado, T., Duran, D., Kaplan, A. H., & Wenger, N. (2001). A comparison of multiple measures of adherence to HIV protease inhibitors. *Annals of Internal Medicine*, *134*, 968–977. 685
- Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. *Annals of Internal Medicine*, *131*, 81–87. 690
- Marinker, M. (1997). From compliance to concordance: Achieving shared goals in medicine taking. *British Medical Journal*, *314*, 747–748.
- Morin, M., & Moatti, J-P. (1996). Observance et essais thérapeutiques: Obstacles psychosociaux dans la recherche sur le traitement de l'infection à VIH. *Natures, Sciences, Sociétés*, *3*, 2–15. 695
- Morin, M., Munzenberger, N., Souville, M., Moatti, J-P., & Gastaut, J. A. (1996). *Biases in recruitment and non-compliance in AIDS clinical trials*. XIth International Conference on AIDS, Vancouver, Canada. 700
- Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., Kumar, P. N., Mintz, L., Wallach, F. R., & Nemo, G. J. (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. *Annals of Internal Medicine*, *135*, 17–26. 705
- Newcomb, M. D. (1990). What structural modelling techniques can tell us about social support. In I. G. Sarason, B. R. Sarason, & G. R. Pierce (Eds.), *Social support: An interactional view* (pp. 26–63). New York: Wiley. 710
- Newcomb, M. D. (1994). Drug use and intimate relationships among women and men: Separating specific from general effects in prospective data using structural equation models. *Journal of Consulting and Clinical Psychology*, *62*, 463–476. 715
- Nieuwkerk, P. T., Gisolf, E. H., Reijers, M. H., Lange, J. M., Danner, S. A., & Spranger, M. A. (2001). Long term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. *AIDS*, *15*, 1985–1991.
- Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Annals of Internal Medicine*, *133*, 21–30. 720
- Perno, C. F., Ceccherini-Silberstein, F., De Luca, A., Cozzi-Lepri, A., Gori, C., & Cingolani, A. (2002). Virologic correlates adherence to antiretroviral medications and therapeutic failure. *Journal of Acquired Immune Deficiency Syndromes*, *31*, S118–S122. 725
- Reynolds, N. R., & Alonzo, A. A. (1998). HIV informal care: Emergent conflict and growth. *Research in Nursing and Health*, *21*, 251–260. 730
- Reynolds, N. R., & Alonzo, A. A. (2000). Self-regulation: The commonsense Model of Illness Representation. In V. H. Rice (Ed.), *Handbook of stress and coping* (pp. 483–495). Thousand Oaks: Sage.
- Reynolds, N. R. (2003). The problem of antiretroviral adherence: A self-regulatory model for intervention. *Aids Care*, *15*, 117–124. 735
- Reynolds, N. R., Testa, M. A., Marc, L. G., Chesney, M. A., & Neidig, J. (2004). Factors influencing medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: A multicenter, cross-sectional study. *Aids Behavior*, *8*, 141–150. 740
- Roberts, K. J. (2002). Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. *AIDS Patient Care and STDs*, *16*, 43–50. 745
- Rokeach, M. (1973). *The nature of human values*. New York: Free Press.
- Royal Pharmaceutical Society of Great Britain. (1997). *From compliance to concordance: Achieving shared goals in medicine taking*. London. 750

- Schwartz, S. H. (1992). Universals in the content and the structure of values: Theoretical advances and empirical tests in 20 countries. In M. P. Zanna (Ed.), *Advances in experimental social psychology* (vol. 25, pp. 1–65). New York: Academic Press. 755
- Simoni, J. M., Frick, P. A., Lockhart, D., & Liebovitz, D. (2002). Mediators of social support and antiretroviral adherence among an indigent population in New York. *AIDS Patient Care and STDs, 16*, 431–439. 760
- Simoni, J. M., Frick, P. A., Pantalone, D. W., & Turner, B. J. (2003). Antiretroviral adherence intervention: A review of current literature and ongoing studies. *Topics in HIV Medicine, 11*, 185–198. 765
- Simoni, J. M., Kerwin, J. F., & Martone, M. M. (2002). Spirituality and psychological adaptation among women with HIV/AIDS: Implications for counseling. *Journal of Counseling in Psychology, 49*, 139–147. 770
- Simoni, J. M., Frick, P. A., & Huang, B. (2006). A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. *Health Psychology, 25*, 74–81. 775
- Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M. H., & Yu, V. L. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. *AIDS Care, 8*, 261–269. 780
- Starace, F., Massa, A., & Amico, K. R. (2006). Adherence to antiretroviral therapy: An empirical test of the information-motivation-behavioral skills model. *Health Psychology, 25*, 153–162.
- Tarquinio, C., Fischer, G.-N., Gauchet, A., Dodeler, V., Grégoire, A., & Romary, B. (2003). Compliance et concept de soi chez des patients atteints par le VIH: Une approche dynamique du soi. *Revue Internationale de Psychologie Sociale, 16*, 21–54.
- Tarquinio, C., Fischer, G.-N., & Barracho, C. (2002). Le patient face aux traitements: Compliance et relation médecin-patient. In Fischer, G.-N. (Ed.), *Traité de Psychologie de la Santé*. Paris: Dunod. 785
- Tarquinio, C., & Fischer, G.-N. (2001). Therapeutic compliance methodologies in HIV infection treatment: A comparative study. *Swiss Journal of Psychology, 60*, 136–160. 790
- Tarquinio, C., Fischer, G.-N., & Grégoire, A. (2000). La compliance chez des patients atteints par le VIH: Validation d'une échelle française et mesure de variables psychosociales. *Revue Internationale de Psychologie Sociale, 13*, 61–91. 795
- Tucker, L. R., & Lewis, C. (1973). A reliability coefficient for maximum likelihood factor analysis. *Psychometrika, 35*, 417–437.
- Uchino, B. N. (2004). *Social support and physical health: Understanding the health consequences of relationships*. New Haven, CT: Yale University Press. 800
- Van Vaerenbergh, K., De Geest, S., Derdelinckx, I., Bobbaers, H., Carbonez, A., Deschamps, A., et al. (2002). A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. *Antiviral Chemistry and Chemotherapy, 13*, 231–240. 805
- Weaver, K. E., Liabre, M. M., Duran, R. E., Antoni, M. H., Ironson, G., Penedo, F. J., & Schneiderman, N. (2005). A stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART). *Health Psychology, 24*, 385–392. 810
- Weinman, J., Petrie, K., Moss-Morris, R., & Horne, R. (1996). The illness perception questionnaire: A new method for assessing the cognitive representation of illness. *Psychology and Health, 11*, 431–445.
- Zinnbauer, B. J., Pargament, K. I., Cole, B., Rye, M. S., Belavich, T. G., & Hipp, K. M. et al. (1997). Religion and spirituality: Un-fuzzifying the fuzzy. *Journal for the Scientific Study of Religion, 36*, 549–564. 815